Top

Molecular Cancer

Published in:

Open Access 01-12-2009 | Research

Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis

Authors: Keqiang Zhang, Shuya Hu, Jun Wu, Linling Chen, Jianming Lu, Xiaochen Wang, Xiyong Liu, Bingsen Zhou, Yun Yen

Published in: Molecular Cancer | Issue 1/2009

Abstract

Background

In addition to its essential role in ribonucleotide reduction, ribonucleotide reductase (RNR) small subunit, RRM2, has been known to play a critical role in determining tumor malignancy. Overexpression of RRM2 significantly enhances the invasive and metastatic potential of tumor. Angiogenesis is critical to tumor malignancy; it plays an essential role in tumor growth and metastasis. It is important to investigate whether the angiogenic potential of tumor is affected by RRM2.

Results

We examined the expression of antiangiogenic thrombospondin-1 (TSP-1) and proangiogenic vascular endothelial growth factor (VEGF) in two RRM2-overexpressing KB cells: KB-M2-D and KB-HURs. We found that TSP-1 was significantly decreased in both KB-M2-D and KB-HURs cells compared to the parental KB and mock transfected KB-V. Simultaneously, RRM2-overexpressing KB cells showed increased production of VEGF mRNA and protein. In contrast, attenuating RRM2 expression via siRNA resulted in a significant increased TSP-1 expression in both KB and LNCaP cells; while the expression of VEGF by the two cells was significantly decreased under both normoxia and hypoxia. In comparison with KB-V, overexpression of RRM2 had no significant effect on proliferation in vitro, but it dramatically accelerated in vivo subcutaneous growth of KB-M2-D. KB-M2-D possessed more angiogenic potential than KB-V, as shown in vitro by its increased chemotaxis for endothelial cells and in vivo by the generation of more vascularized tumor xenografts.

Conclusion

These findings suggest a positive role of RRM2 in tumor angiogenesis and growth through regulation of the expression of TSP-1 and VEGF.

Available only for authorised users

Nordlund P, Reichard P: Ribonucleotide reductases. Annu Rev Biochem. 2006, 75: 681-706. 10.1146/annurev.biochem.75.103004.142443CrossRefPubMed

Engstrom Y, Eriksson S, Jildevik I, Skog S, Thelander L, Tribukait B: Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. J Biol Chem. 1985, 260: 9114-9161.PubMed

Zhou B, Yen Y: Characterization of the human ribonucleotide reductase M2 subunit gene; genomic structure and promoter analyses. Cytogenet Cell Genet. 2001, 95: 52-59. 10.1159/000057017CrossRefPubMed

Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, Nakamura Y: A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 2000, 404: 42-49. 10.1038/35003506CrossRefPubMed

Guittet O, Håkansson P, Voevodskaya N, Gräslund A, Arakawa H, Nakamura Y, Thelander L: Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem. 2001, 276: 40647-40651. 10.1074/jbc.M106088200CrossRefPubMed

Jensen RA, Page DL, Holt JT: Identification of genes expressed in premalignant breast disease by microscopy-directed cloning. Proc Natl Acad Sci USA. 1994, 91: 9257-9261. 10.1073/pnas.91.20.9257PubMedCentralCrossRefPubMed

Schallreuter KU, Elgren TE, Nelson LS, MacFarlan S, Yan-Sze I, Hogenkamp HP: Ribonucleotide diphosphate reductase from human metastatic melanoma. Melanoma Res. 1992, 2: 393-400. 10.1097/00008390-199212000-00014CrossRefPubMed

Liu X, Zhou B, Xue L, Yen F, Chu P, Un F, Yen Y: Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. Clin Colorectal Cancer. 2007, 6: 374-381. 10.3816/CCC.2007.n.007CrossRefPubMed

Fan H, Huang A, Villegas C, Wright JA: The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. Proc Natl Acad Sci USA. 1997, 94: 13181-13186. 10.1073/pnas.94.24.13181PubMedCentralCrossRefPubMed

10.

Gautam A, Li ZR, Bepler G: RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene. 2003, 22: 2135-2142. 10.1038/sj.onc.1206232CrossRefPubMed

11.

Cao MY, Lee Y, Feng NP, Xiong K, Jin H, Wang M, Vassilakos A, Viau S, Wright JA, Young AH: Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. Clin Cancer Res. 2003, 9: 4553-61.PubMed

12.

Fan H, Villegas C, Huang A, Wright JA: The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res. 1998, 58: 1650-1653.PubMed

13.

Fan H, Villegas C, Wright JA: Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. Proc Natl Acad Sci USA. 1996, 93: 14036-14040. 10.1073/pnas.93.24.14036PubMedCentralCrossRefPubMed

14.

Liu X, Zhou B, Xue L, Shih J, Tye K, Lin W, Qi C, Chu P, Un F, Wen W, Yen Y: Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells. Clin Cancer Res. 2006, 12: 6337-6344. 10.1158/1078-0432.CCR-06-0799CrossRefPubMed

15.

Zhou B, Tsai P, Ker R, Tsai J, Ho R, Yu J, Shih J, Yen Y: Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis. 1998, 16: 43-49. 10.1023/A:1006559901771CrossRefPubMed

16.

Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE: RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene. 2004, 23: 1539-1548. 10.1038/sj.onc.1207272CrossRefPubMed

17.

Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995, 1: 27-31. 10.1038/nm0195-27CrossRefPubMed

18.

Carmeliet P: Angiogenesis in health and disease. Nat Med. 2003, 9: 653-660. 10.1038/nm0603-653CrossRefPubMed

19.

Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996, 86: 353-364. 10.1016/S0092-8674(00)80108-7CrossRefPubMed

20.

Semenza GL: Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med. 2003, 54: 17-28. 10.1146/annurev.med.54.101601.152418CrossRefPubMed

21.

Ren B, Yee KO, Lawler J, Khosravi-Far R: Regulation of tumor angiogenesis by Thrombospondin-1. Biochim Biophys Acta. 2006, 1765 (2): 178-188.PubMed

22.

Rak J, Yu JL, Kerbel RS, Coomber BL: What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors?. Cancer Res. 2002, 62: 1931-1934.PubMed

23.

Hanahan D, Weinberg RA: The Hallmarks of Cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9CrossRefPubMed

24.

Short SM, Derrien A, Narsimhan RP, Lawler J, Ingber DE, Zetter BR: Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by β₁ integrins. J Cell Biol. 2005, 168: 643-653. 10.1083/jcb.200407060PubMedCentralCrossRefPubMed

25.

Heidel JD, Liu JY, Yen Y, Zhou B, Heale BS, Rossi JJ, Bartlett DW, Davis ME: Potent siRNA Inhibitors of Ribonucleotide Reductase Subunit RRM2 Reduce Cell Proliferation In vitro and In vivo. Clin Cancer Res. 2007, 13: 2207-2215. 10.1158/1078-0432.CCR-06-2218CrossRefPubMed

26.

Zhou B, Ker R, Ho R, Yu J, Zhao YR, Shih J, Yen Y: Determination of deoxyribonucleoside triphosphate pool sizes in ribonucleotide reductase cDNA transfected human KB cells. Biochem Pharmacol. 1998, 55: 1657-1665. 10.1016/S0006-2952(98)00042-2CrossRefPubMed

27.

Bergers G, Benjamin LE: Angiogenesis: Tumorigenesis and the angiogenic switch. Nature Reviews Cancer. 2003, 3: 401-410. 10.1038/nrc1093CrossRefPubMed

28.

Harris AL: Hypoxia – a key regulatory factor in tumor growth. Nat Rev Cancer. 2002, 2: 38-47. 10.1038/nrc704CrossRefPubMed

29.

Bando H, Weich HA, Brokelmann M, Horiguchi S, Funata N, Ogawa T, Toi M: Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer. 2005, 92: 553-561.PubMedCentralPubMed

30.

Koukourakis MI, Giatromanolaki A, Thorpe PE, Brekken RA, Sivridis E, Kakolyris S, Georgoμlias V, Gatter KC, Harris AL: Vascular Endothelial Growth Factor/KDR Activated Microvessel Density versus CD31 Standard Microvessel Density in Non-Small Cell Lung Cancer. Cancer Res. 2000, 60: 3088-3095.PubMed

31.

Graff P, Seim J, Amellem Ø, Arakawa H, Nakamura Y, Andersson KK, Stokke T, Pettersen EO: Counteraction of pRb-dependent protection after extreme hypoxia by elevated ribonucleotide reductase. Cell Prolif. 2004, 37: 367-383. 10.1111/j.1365-2184.2004.00319.xCrossRefPubMed

32.

Gutierrez LS, Suckow M, Lawler J, Ploplis VA, Castellino FJ: Thrombospondin 1-a regulator of adenoma growth and carcinoma progression in the APC^Min/+ mouse model. Carcinogenesis. 2003, 24: 199-207. 10.1093/carcin/24.2.199CrossRefPubMed

33.

Yang QW, Liu S, Tian Y, Salwen HR, Chlenski A, Weinstein J, Cohn SL: Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res. 2003, 63: 6299-6310.PubMed

34.

Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA: Ras modμlates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell. 2003, 3: 219-231. 10.1016/S1535-6108(03)00030-8CrossRefPubMed

35.

Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML: Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA. 2001, 98: 12485-12490. 10.1073/pnas.171460498PubMedCentralCrossRefPubMed

36.

Duxbury MS, Whang EE: RRM2 induces NF-kappaB-dependent MMP-9 activation and enhances cellular invasiveness. Biochem Biophys Res Commun. 2007, 354: 190-196. 10.1016/j.bbrc.2006.12.177CrossRefPubMed

37.

Xue L, Zhou B, Liu X, Qiu W, Jin Z, Yen Y: Wild-Type p53 regulates human ribonucleotide reductase by protein-protein Interaction with p53R2 as well as RRM2 Subunits. Cancer Res. 2003, 63: 980-986.PubMed

38.

Volpert OV, Dameron KM, Bouck N: Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene. 1997, 27 (14): 1495-502. 10.1038/sj.onc.1200977. 10.1038/sj.onc.1200977CrossRef

Title: Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis
Authors: Keqiang Zhang
Shuya Hu
Jun Wu
Linling Chen
Jianming Lu
Xiaochen Wang
Xiyong Liu
Bingsen Zhou
Yun Yen
Publication date: 01-12-2009
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2009
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-8-11

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2009

Limited copy number - high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies

CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors

The tumor suppressor gene TRC8/RNF139 is disrupted by a constitutional balanced translocation t(8;22)(q24.13;q11.21) in a young girl with dysgerminoma

Altered regulation of metabolic pathways in human lung cancer discerned by 13C stable isotope-resolved metabolomics (SIRM)

Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor

Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer